Business Wire

CA-ARYAKA

23.3.2021 13:02:07 CET | Business Wire | Press release

Share
Aryaka’s Fifth Annual Global State of the WAN Report Reveals Network Insights From 1,350 Global Enterprises

Aryaka® , the leader in fully managed Cloud-First WAN solutions, today published its fifth annual 2021 State of the WAN report, the industry’s foremost survey into global SD-WAN and SASE planning. Key trends identified in this year’s report include:

  • Accelerating fusion of networking and security planning, with almost a third of enterprises stating that they are already deploying what they consider to be a secure access service edge (SASE) architecture
  • A hybrid work environment that will persist after the pandemic recedes, with over 80% stating that they expect over a quarter of workers to remain remote, and over two-thirds desiring flexibility between on-premises and remote deployments
  • Continued WAN and application growth, resulting in increased network complexity. The number of enterprises reporting they’re deploying over 500 distinct applications has grown to 46%. 37% of enterprises identify complexity as their number one network concern
  • 43% of enterprises identify application performance as an underlying driver for WAN transformation. However, WAN transformations have slowed this year due to the pandemic
  • Over 70% of enterprises intend to move to managed services versus just 18% who prefer the autonomy of a do-it-yourself WAN solution

"Every year I look forward to Aryaka's high quality State of the WAN report for information on industry trends,” said Scott Raynovich, founder and chief analyst at Futuriom. “This year, the report reflects many of the same trends we are seeing at Futuriom, which include the ongoing integration of cloud-based networking services and security -- otherwise known as Secure Access Service Edge (SASE) -- as well as strong demand for virtualized networking solutions targeted at Work from Anywhere (WFA) and hybrid work environments. It's a good read!”

Year-on-Year Trends with Changing Challenges and Priorities

The WAN continues to extend its reach, with the number of enterprises connecting to over 100 inter-regional sites growing by 50%, from 19% in 2020 to 28% in 2021. This is coupled with continued application growth, with the number of enterprises stating that they’ve deployed over 500 distinct applications growing to 46%, compared to 32% in 2021. As evidence of collaboration traction, Zoom was identified as critical by 36% in 2021, up from 25% in 2020.

One finding that did not noticeably change year-on-year is complexity, which was identified by 36% of enterprises as their number one network issue. Interestingly, those who identified cost as a major issue grew to 20% in 2021 from 16% in 2020, a 25% increase. This may be attributed to cloud or MPLS cost concerns.

Overall, investment priorities did see recede in some areas, due to tactical pandemic concerns driving near-term planning. For example, only 17% of respondents plan to conduct an SD-WAN/SASE-driven network refresh this year versus 29% in 2020. However, combining this with remote access upgrades, a new entry at 22%, and security, at 21%, results in strong momentum going into 2021. In contrast, LTE/5G experienced growth from 24% in 2020 to 31% in 2021. Finally, VPN investment is at 31% this year versus 27% in 2020. Aryaka believes the new remote workforce, due to the pandemic, led to this VPN increase.

For actual deployment, managed services still reign supreme at 71%, versus 18% who are looking for a do-it-yourself (DIY) solution. Many enterprises are also further along the deployment lifecycle, with 26% evaluating SD-WAN this year, up from 22% in 2020. This increasing market maturity is reflected in a drop in identified barriers to SD-WAN adoption. Enterprises are less concerned that the WAN service won’t address application performance, coming in at 36% this year, versus 43% in 2020, with corresponding drops in SLA concerns, technology maturity, and lack of skills.

A Closer Look at SASE and the Rise of the Hybrid Workplace

Enterprise SASE deployment plans are accelerating, with 29% stating that they are already deploying what they consider to be a SASE architecture. Another 56% are planning to deploy a SASE architecture in the next 12-24 months. As part of a complete SASE architecture, the top capability identified was SD-WAN transport at 34%. And for deployment, over half state that they prefer a solution that includes technology from both their WAN vendor and security specialists, spanning across cloud and the edge.

When the pandemic hit, workers around the world migrated from their offices to their homes, a shift that will also impact future planning and investment throughout 2021. More than half (59%) of the respondents stated they expect 25-50% of their workers to remain remote, while 21% say they are planning for more than 50% of their workforce to continue working from home. Businesses are also prioritizing flexibility, with 63% stating that they consider the ability to quickly move resources between on-premises and remote to be very important.

“The fifth edition of the Global State of the WAN is bigger and better than ever, with survey inputs and insights from over 1350 Enterprises worldwide,” said Shashi Kiran, CMO of Aryaka. “On behalf of Aryaka Networks, I would like to express my gratitude to those who participated in this survey, and hope this serves as an excellent resource and guidebook for all those CIOs, network, cloud and security practitioners to leverage and proactively Plan their WAN™. Of particular interest are the trends focusing on SD-WAN and SASE deployments.”

Study Methodology

The Fifth Annual Global Aryaka 2021 State of the WAN study surveyed over 1350 global IT and network practitioners at enterprises spanning all verticals, headquartered in NA, APAC and EMEA. The survey asked respondents about their networking and performance challenges, priorities and their plans for 2021 and beyond.

Aryaka to Host 2021 The State of the WAN Webinars

Join us at the following dates/times for a lively panel discussion on the “Aryaka 2021 Global State of the WAN.” Regional observations will also be presented:

● North America

March 23, 1pm EST, 10am PST

Register Here

● EMEA

March 23, 3pm GMT

Register Here

● APAC

March 24, 930am IST, Noon Beijing

Register Here

This interactive format allows the panel of experts to deep dive into the Fifth annual State of the WAN report, which will include further analysis of the key findings driving digital transformation.

Download Report Here : https://www.aryaka.com/state-of-wan-2021/
Download Infographic Here : https://www.aryaka.com/docs/aryaka-state-of-the-wan-2021-infographic.pdf

Additional Resources:

  1. Aryaka Managed SD-WAN as-a-Service . This datasheet explains how the Aryaka SmartServices platform is built for the Cloud-First world. Specifically, this means there are no products to buy, and no inventory, deployment hassles, patches or configurations to worry about.
  2. Aryaka’s Cloud-First WAN for Dummies . This e-book explains everything you need to know about consuming your network as-a-Service, how to achieve fully integrated security, and how to make your network as easy as your cloud.

For more on Aryaka, please visit: https://www.aryaka.com/
Visit the Aryaka blog: https://www.aryaka.com/blog/
Follow Aryaka on Twitter: @AryakaNetworks
Visit Aryaka on LinkedIn: https://www.linkedin.com/company/aryaka-networks/

About Aryaka

Aryaka, the Cloud-First WAN company, brings agility, simplicity and a great experience to consuming the WAN-as-a-service for network and security. The company provides an optimized global network and innovative technology stack, delivering the industry’s #1 managed SD-WAN service and setting the gold standard for application performance. Aryaka’s SmartServices platform offers connectivity, application acceleration, security, cloud networking and insights that leverage global orchestration and provisioning. The company’s customers include hundreds of global enterprises including several in the Fortune 100.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye